{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T12:16:15Z","timestamp":1771935375912,"version":"3.50.1"},"reference-count":6,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T00:00:00Z","timestamp":1763683200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,2,24]]},"abstract":"<jats:p>This descriptive, retrospective study examines the incidence of symptomatic hypomagnesaemia in patients with psoriasis treated with ciclosporin, using data from the British Association of Dermatologists Biologic and Immunomodulators Register. Our findings suggest no significant difference in hypomagnesaemia rates between patients exposed and unexposed to ciclosporin, indicating that routine serum magnesium monitoring may not be necessary unless additional risk factors are present.<\/jats:p>","DOI":"10.1093\/ced\/llaf520","type":"journal-article","created":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T13:30:13Z","timestamp":1763645413000},"page":"504-505","source":"Crossref","is-referenced-by-count":0,"title":["Does ciclosporin cause symptomatic hypomagnesaemia in patients with psoriasis included in the British Association of Dermatologists Biologics and Immunomodulators Registry pharmacovigilance registry?"],"prefix":"10.1093","volume":"51","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6780-0975","authenticated-orcid":false,"given":"Eleanor","family":"Clarke","sequence":"first","affiliation":[{"name":"Department of Dermatology, Portsmouth University Hospitals NHS Trust, St Mary\u2019s Hospital , Portsmouth ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8359-9017","authenticated-orcid":false,"given":"Birgitta","family":"van Bodegraven","sequence":"additional","affiliation":[{"name":"Department of Research and Publishing, British Association of Dermatologists , London ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexa R","family":"Shipman","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Portsmouth University Hospitals NHS Trust, St Mary\u2019s Hospital , Portsmouth ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,11,21]]},"reference":[{"key":"2026022406170116100_llaf520-B1","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1111\/j.1365-2265.2011.04092.x","article-title":"How should hypomagnesaemia be investigated and treated?","volume":"75","author":"Ayuk","year":"2011","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2026022406170116100_llaf520-B2","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1093\/ndt\/gft498","article-title":"Magnesium loss in cyclosporine-treated patients is related to renal epidermal growth factor downregulation","volume":"29","author":"Ledeganck","year":"2014","journal-title":"Nephrol Dial Transplant"},{"key":"2026022406170116100_llaf520-B3","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1016\/S0140-6736(84)91556-3","article-title":"Association between cyclosporin neurotoxicity and hypomagnesaemia","volume":"2","author":"Thompson","year":"1984","journal-title":"Lancet"},{"key":"2026022406170116100_llaf520-B4","doi-asserted-by":"publisher","DOI":"10.21037\/jlpm-22-6","article-title":"Investigative algorithms for disorders affecting plasma magnesium: a narrative review","volume":"7","author":"Darragh-Hickey","year":"2022","journal-title":"J Lab Precis Med"},{"issue":"Suppl 36","key":"2026022406170116100_llaf520-B5","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/j.1365-2133.1990.tb02882.x","article-title":"Side-effect profile of cyclosporin A in patients treated for psoriasis","volume":"122","author":"Krupp","year":"1990","journal-title":"Br J Dermatol"},{"key":"2026022406170116100_llaf520-B6","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1111\/bjd.17587","article-title":"British Association of Dermatologists guidelines for the safe and effective prescribing of oral ciclosporin in dermatology 2018","volume":"180","author":"Berth-Jones","year":"2019","journal-title":"Br J Dermatol"}],"container-title":["Clinical and Experimental Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ced\/advance-article-pdf\/doi\/10.1093\/ced\/llaf520\/65465350\/llaf520.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/51\/3\/504\/65465350\/llaf520.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/51\/3\/504\/65465350\/llaf520.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T11:17:07Z","timestamp":1771931827000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ced\/article\/51\/3\/504\/8340092"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,21]]},"references-count":6,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,11,21]]},"published-print":{"date-parts":[[2026,2,24]]}},"URL":"https:\/\/doi.org\/10.1093\/ced\/llaf520","relation":{},"ISSN":["0307-6938","1365-2230"],"issn-type":[{"value":"0307-6938","type":"print"},{"value":"1365-2230","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,3]]},"published":{"date-parts":[[2025,11,21]]}}}